Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Windtree Therapeutics ( (WINT) ) has shared an update.
Windtree Therapeutics, Inc. announced a 1-for-50 reverse stock split of its common stock, effective February 20, 2025, with the aim of meeting Nasdaq’s $1.00 minimum bid price requirement. This strategic move, approved by stockholders on February 3, 2025, is expected to consolidate shares and increase the stock price, impacting the company’s trading on the Nasdaq Capital Market.
More about Windtree Therapeutics
Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio includes istaroxime, a Phase 2 candidate for acute heart failure with SERCA2a activating properties, and other preclinical candidates for heart failure and oncology applications. The company also engages in a licensing business model with partnership out-licenses.
YTD Price Performance: -59.59%
Average Trading Volume: 7,335,250
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.52M
For an in-depth examination of WINT stock, go to TipRanks’ Stock Analysis page.
